Communiqués Century Therapeutics, Inc.

Actions

IPSC

US15673T1007

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 16/07/2024			Varia. 5j.	Varia. 1 janv.
3,29 ^USD	+19,64 %		+37,66 %	-0,90 %

18/06	Century Therapeutics propose une offre secondaire de 7,87 millions d'actions	MT
17/06	CENTURY THERAPEUTICS, INC. : Piper Sandler réitère son opinion positive sur le titre	ZM

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Century Therapeutics : Corporate Overview June 2024	03/06	PU
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting	03/06	GL
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting	03/06	AQ
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting	13/05	AQ
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting	10/05	GL
Century Therapeutics : Corporate Overview May 2024	09/05	PU
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates	09/05	GL
Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit	24/04	AQ
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit	23/04	GL
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit	23/04	AQ
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics	11/04	GL
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting	08/04	GL
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	19/03	GL
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates	14/03	GL
Century Therapeutics : Corporate Overview March 2024	11/03	PU
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting	06/03	GL
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	01/02	GL
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits	09/12	AQ
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits	09/12	GL
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus	06/12	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Century Therapeutics, Inc.

Actions

IPSC

US15673T1007

Communiqués

Filtres